简繁EN
Antengene

Company Introduction

3D Medicines Inc. is a commercialization stage bio-pharmaceutical company, focused on the field of cancer treatment. With a mission to help people with cancer live longer and better, we commit to developing a new generation of therapies for cancer patients around the world, following a future when cancer is managed as a chronic disease. Our differentiated or world-leading portfolio of 12 drug candidates with clinical benefit includes eight in clinical or commercialization stage. Our global first subcutaneously-injectable PD-L1 antibody Envafolimab co-developed by partner has submitted BLA in China. The global first-in-class peptide cancer vaccine 3D189 and GAS6 decoy protein 3D229 are in an ongoing global Phase III trial. Our in-house developed multi-target kinase inhibitor 3D011 has also entered clinical development.We currently have an international team of nearly 200 R&D, manufacture and commercialization members. please visit www.3d-medicines.com

MORE

February 2021

In February, 2021, the construction of 3D Medicines’ R&D and Manufacturing Center started in Xuzhou, Jiangsu.

04
04
04
04
04
04
March 2020
October 2020
November 2020
December 2020
January 2021
February 2021
In March, 2020, a partnership with Alphamab and Simcere Pharmaceuticals was formed for the development and commercialization of KN035 in China.
In October, 2020, we received $140 million investment from Simcere Pharmaceuticals, Efung Capital, China Capital Management and other institutions.
In November, 2020, Envafolimab (KN035), the world's first PD-L1 antibody drug given via subcutaneous Injection submitted new drug application for marketing in China.
In December, 2020, the NDA of Envafolimab (KN035) was officially accepted by the NMPA.
In January, 2021, NDA of Envafolimab (KN035) was granted NMPA Priority Review.
In February, 2021, the construction of 3D Medicines’ R&D and Manufacturing Center started in Xuzhou, Jiangsu.

PipelineThe company has established a multi-core collaborative clinical pipeline

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Marketing

Candidate
Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase Ⅱ

Phase Ⅲ

NDA

Marketing

  • Envafolimab
  • PD-L1
  • Global

  • MSI-H/dMMR，mono，2L+，ORR，pan-cancer

  • BTC，combo with chemo vs. chemo, randomized，OS，1L

  • SC，mono，+ipilimumab，ORR，2L+

  • NSCLC，combo，1L

  • NSCLC，combo，2L+

  • HER2+ GC，combo，1L

  • UC，mono vs. BSC, 1L maintenance

  • TMB-H,single arm,mono， 2L+

  • endometrial cancer, single arm, combo with lenvatinib, 2L+

  • HCC，combo with VEGF inhibitor，2L+

  • RCC，combo with VEGF inhibitor，1L/2L+

MORE

  • 3D189
  • WT1
  • Great China

  • multiple indications

  • AML,MPM,OC,CRC,SCLC,TNBC,MM

MORE

  • 3D229
  • GAS6/AXL
  • Great China

  • NSCLC,OC,RCC,BC

  • OC,RCC,BC

MORE

  • 3D1001
  • COX-2
  • China

  • post-surgical dental pain、cancer pain

MORE

  • 3D1002
  • EP-4
  • China

  • cancer pain、osteoarthritis

MORE

  • 3D185
  • FGFR1/2/3
  • Global

  • BTC/mUC

MORE

  • 3D011
  • PSMA+
    targeted TKI
  • Worldwide

  • HCC/Prostate cancer

MORE

  • 3D197
  • CD47
  • Great China

  • multiple indications

  • multiple indications

MORE

  • 3D057
  • CD3+PD-L1
  • Great China

  • Multiple indications

MORE

  • 3D059
  • 3D189
  • Greater China

  • Multiple indications

MORE

  • 3D060
  • undisclosed
  • Globa

  • Multiple indications

MORE

  • 3D062
  • undisclosed
  • Global

  • multiple indications

MORE

Pipeline

  1. Envafolimab
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D197
  9. 3D057
  10. 3D059
  11. 3D060
  12. 3D062

CEO QUOTATION

"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.

With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."


-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.

MORE

Company News

MORE

Copyright © 3D Medicines Inc. All Rights Reserved